Why this major drugmaker no longer has an ‘IT department’

Fortune2024-11-14

When Gabriele Ricci became chief data and technology officer at Takeda Pharmaceutical, one of the biggest cultural changes he made was eliminating the term “information technology.” “We don’t use the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483565948?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aA_OfS6x_7DpM86bYspl.w--~B/aD0xMDAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/416640ec97e8bae8fa4501a40f66cd22","is_english":true,"pubTime":"2024-11-14 00:46","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483565948","market":"us","top_or_hot":-1,"title":"Why this major drugmaker no longer has an ‘IT department’","media":"Fortune","content":"<div>\n<p>When Gabriele Ricci became chief data and technology officer at Takeda Pharmaceutical, one of the biggest cultural changes he made was eliminating the term “information technology.”\n“We don’t use the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-major-drugmaker-no-longer-164604620.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why this major drugmaker no longer has an ‘IT department’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy this major drugmaker no longer has an ‘IT department’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 00:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-major-drugmaker-no-longer-164604620.html><strong>Fortune</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Gabriele Ricci became chief data and technology officer at Takeda Pharmaceutical, one of the biggest cultural changes he made was eliminating the term “information technology.”\n“We don’t use the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-major-drugmaker-no-longer-164604620.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFSS7M15.SGD","symbol_name":"Janus Henderson Balanced A Acc SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/why-major-drugmaker-no-longer-164604620.html","article_id":"2483565948","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aA_OfS6x_7DpM86bYspl.w--~B/aD0xMDAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/416640ec97e8bae8fa4501a40f66cd22"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483565948","pubTimestamp":1731516364,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"When Gabriele Ricci became chief data and technology officer at Takeda Pharmaceutical, one of the biggest cultural changes he made was eliminating the term “information technology.”“We don’t use the word IT anymore,” says Ricci, who was appointed to lead the data, digital, and technology function at the Japan-based pharmaceutical giant since 2022. “We truly believe our function is a business function.”Three years ago, 80% of the company’s technology needs were performed by external contractors. Ricci disliked relying so heavily on third parties, and Takeda hired thousands of engineers, data scientists, and architects. He put them in three major innovation centers, called “digital factories” internally, in India, Mexico, and Slovakia to co-develop technology with various business functions.Takeda is both buying and building generative AI tools, using models from providers including Microsoft, OpenAI, Anthropic, and Amazon Web Services. In areas where Takeda wants to retain a more clear ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","IE00B4YYXB79.USD":"PIMCO BALANCED INCOME AND GROWTH \"E\" (USD) ACC","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","IE0034235295.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"A\" (USD) ACC","IE00BDCRKT87.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","TAK":"武田制药","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","BK4534":"瑞士信贷持仓","BK4567":"ESG概念","BK4576":"AR","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4533":"AQR资本管理(全球第二大对冲基金)","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","BK4587":"ChatGPT概念","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","MSFT":"微软","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4577":"网络游戏","BK4527":"明星科技股","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","BK4588":"碎股","BK4550":"红杉资本持仓","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","IE0009G5SDU7.USD":"PIMCO BALANCED INCOME AND GROWTH \"M\" (USD) INC","BK4503":"景林资产持仓","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","IE000ITXATA3.USD":"PIMCO BALANCED INCOME AND GROWTH \"M\" (USD) ACC","BK4528":"SaaS概念","BK4097":"系统软件","BK4581":"高盛持仓","IE000KEQY171.SGD":"PIMCO BALANCED INCOME AND GROWTH \"M\" (SGDHDG) INC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4516":"特朗普概念","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc"},"translate_title":"为什么这家主要制药商不再有“IT部门”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9,"MSFT":0.83},"content_text":"When Gabriele Ricci became chief data and technology officer at Takeda Pharmaceutical, one of the biggest cultural changes he made was eliminating the term “information technology.”\n“We don’t use the word IT anymore,” says Ricci, who was appointed to lead the data, digital, and technology function at the Japan-based pharmaceutical giant since 2022. “We truly believe our function is a business function.”\nWhile that may seem mostly symbolic, Takeda, which develops treatments for oncology, rare diseases, and gastrointestinal and inflammation, has substantially reorganized the technology function under Ricci's leadership. Ricci reports directly to CEO Christophe Weber, giving the technology division a prime position within the C-suite. His predecessor had reported to the chief financial officer.\nThree years ago, 80% of the company’s technology needs were performed by external contractors. Ricci disliked relying so heavily on third parties, and Takeda hired thousands of engineers, data scientists, and architects. He put them in three major innovation centers, called “digital factories” internally, in India, Mexico, and Slovakia to co-develop technology with various business functions.\nThis structure represents a more federated approach, Ricci says, adding “we have a scientific pipeline and a digital pipeline managed together in symbiosis.\" \nRicci has spent his entire technology career in the pharmaceutical industry, beginning at Bristol-Myers Squibb, then Johnson & Johnson, Novartis, and Shire. He joined Takeda after it acquired Shire for $62 billion in 2019.\nIn recent years, he says the environment for pharmaceutical companies has become more volatile. There are more macroeconomic tensions, greater pressure on costs, and higher expectations from customers. “If you are not investing now in digital and enabling a big transformation, we risk our existence,” warns Ricci.\nTakeda has also gotten more aggressive about upskilling employees. More than half of the company’s workforce has taken virtual or in-person courses and training for new technologies, like AI. There are thousands of classes available in over 100 different languages.\nThe focus on upskilling has included new generative AI tools like a chatbot called “myAibou,”—aibou means \"companion\" in Japanese—that has been used by more than 24,000 Takeda employees for summarizing, content creation, and other repetitive tasks. Takeda says generative AI is being used across the company in functions ranging from R&D to supply chain to operations. All of Takeda's AI and generative AI tools are built to be auditable, monitored for bias and discrimination, and adhere to the company's ethical AI framework, Ricci says.\nTakeda is both buying and building generative AI tools, using models from providers including Microsoft, OpenAI, Anthropic, and Amazon Web Services. In areas where Takeda wants to retain a more clear competitive advantage, like research, it will look to build more of its own models.\nRicci says the combination of multiple models is especially alluring. For writing about medical topics, as an example, one model may be very specialized in picking out scientific information, while another specializes in image processing, and yet another can interpret results from multiple data sets derived from research. \n“There’s not a model that fits all,” says Ricci. “If you just rely on one, it will be less precise than actually orchestrating multiple models together.”\nJohn Kell\nSend thoughts or suggestions to CIO Intelligence here.\nEarlier this week, Fortune hosted its Fortune Global Forum conference in New York, where some of the sessions focused on the intersection of technology and business. In one, the CEOs of Honeywell and Lumen talked about the critical importance of AI and creating a corporate culture that will embrace it. You can catch up with all that happened at the conference through this archive of articles about the individual sessions and video replays.\nBy the way, if you'd like to join us for an upcoming conference, Fortune's Brainstorm AI, in San Francisco, from Dec. 9-10, you can find information and request an invitation here. It will feature top executives from across business and tech, including Rohit Prasad, Amazon's senior vice president and head scientist, artificial general intelligence; Liz Reid, Google’s vice president, search; Christopher Young, Microsoft’s executive vice president of business development, strategy, and ventures; and former NFL quarterback Colin Kaepernick, who has his own AI startup.  \nThis story was originally featured on Fortune.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483565948"}